Form FDA 483 · Issued 2025-11-21
Shilpa Medicare Limited — FDA Form 483 Analysis
FEI: 3018694237 · Sector: Pharmaceuticals & Sterile/OTC Drugs (Drug Manufacturer) · Lead Investigator: Marcus V. Delgado
FDA Form 483 issued to Shilpa Medicare Limited (FEI 3018694237) on 2025-11-21 following an inspection of its drug manufacturer operations in India. The report documents 2 inspection observations centered on Electronic Record Data Integrity (21 CFR Part 11) & Retention, Finished Product Testing, Stability & Expiration Dating.
Get Full Annotated 483 Dossier + CAPA Checklist
Instant PDF + CFR Matrix ($79 vs. Redica's $289)
Need Help Fixing These 2 Citations?
Get matched with a vetted 21 CFR remediation consultant
Observation-by-Observation 21 CFR Breakdown (2)
Observation #1 · 21 CFR 211.42(c)(4)
Electronic Record Data Integrity (21 CFR Part 11) & Retention
FIRST-TIME OBSERVATION
In-Process Material Area
Inspector Observation Language: "Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the storage of in-process materials. Specifically, observed during inspection of Shilpa Medicare Limited on 2025-11-21."
Plain-English Meaning: Uncontrolled spreadsheets, shared laboratory logins, missing audit trails, backdated entries, or failure to retain batch and distribution records for the statutory window.
Standard CAPA Remediation Path: Enforce unique user credentials, immutable audit trails on analytical instruments, controlled form issuance numbers, and 2-year post-expiration record retention.
Observation #2 · 21 CFR 211.122(b)
Finished Product Testing, Stability & Expiration Dating
FIRST-TIME OBSERVATION
Labeling and packaging improperly approved/released
Inspector Observation Language: "Labeling and packaging materials not meeting the appropriate written specifications were [approved] [released for use]. Specifically, observed during inspection of Shilpa Medicare Limited on 2025-11-21."
Plain-English Meaning: Releasing finished batches without verifying strength/potency/microbiological specs, or placing an expiration/best-by date on labels without supporting real-time or accelerated stability data.
Standard CAPA Remediation Path: Require finished-batch microbiological (USP <2021>/<2022>), heavy metal, and active-assay release testing plus ICH stability chamber protocols supporting every label shelf-life claim.